title: [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
abstract: BACKGROUND
  Spironolactone--non-selective mineralocroticoid receptor blocker in patients with chronic heart failure reduces the risk of death. Its efficacy was not assessed in patients with postinfarction (post-MI) left ventricular dysfunction. The purpose of this study was to evaluate the effect of spironolactone on mortality in survivors of acute myocardial infarction with depressed ejection fraction < 30% (EF%) during a 24-month, long-term observation.
  
  
  METHODS
  Study population consisted of 47 patients, 38 men and 9 women aged 41-79 years, mean age 62 +/- 10 years with severe post-MI left ventricular dysfunction (EF% < 30%). Patients were divided into 2 groups according to applied treatment: the group spironolactone (+) - 22 pts who received spironolactone at daily dose 25-50 mg and the group spironolacton (-) - 25 pts not treated with spironolactone. The end point of this observation was mortality from all causes during a 24-month follow-up.
  
  
  RESULTS
  During long-term observation - 19 of 47 patients died (40%). Mortality from all causes in the group spironolactone (+) - 11/22 (50%) was non significantly higher as compared to the group spironolactone (-) - 8/25 (32%).
  
  
  CONCLUSIONS
  In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up.
authors.affiliation: Klinika Kardiologii I Katedry Kardiologii i Kardiochirurgii, Uniwersytetu Medycznego w Lodzi. rutajan@interia.pl
authors.forename: Jan
authors.initials: J
authors.lastname: Ruta
authors.forename: Paweł
authors.initials: P
authors.lastname: Ptaszyński
authors.forename: Marek
authors.initials: M
authors.lastname: Maciejewski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Chizyński
authors.forename: Jan Henryk
authors.initials: JH
authors.lastname: Goch
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002423:Cause of Death; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality*; D013148:Spironolactone / Q000008:administration & dosage*; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone